PVCT Provectus Biopharmaceuticals Dashboard

Provectus Biopharmaceuticals, Inc. is a development stage biopharmaceutical company. It engages in the development of ethical pharmaceuticals for oncology and dermatology indications. Its prescription drugs treats several life threatening cancers including metastatic melanoma, liver cancer, and breast cancer. The company was founded by Eric A. Wachter in 2002 and is headquartered in Knoxville, TN.

Company profile

Ticker

PVCT

Exchange

NASDAQ

Website

www.provectusbio.com/

CEO

Bruce Horowitz

Incorporated

Delaware

Location

Tennessee

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Merck & Co • Allergan • Johnson & Johnson • Abbott Laboratories • Teva- Pharmaceutical Industries • Viatris • Bristol-Myers Squibb • Lilly(Eli) & Co • Warner Chilcott ...

Former names

PROVECTUS PHARMACEUTICAL INC, PROVECTUS PHARMACEUTICALS INC, SPM GROUP INC, ZAMAGE DIGITAL IMAGING INC

SEC CIK

0000315545

Corporate docs

Articles of Incorporation & Bylaws

IRS number

900031917

PVCT stock data

S&P 500

1M 1Y 2Y 5Y

Press releases

Pro users get this 30m faster

Provectus Biopharmaceuticals Announces Publication of Australian Compassionate Use Patients Treated with PV-10® Immunotherapy for In-Transit Melanoma Lesions

31 Mar 21

46% complete response of patients at Melanoma Institute AustraliaFifth published study of in-transit melanoma lesion treatment with single-agent PV-1026-50% complete response (52-86% overall response) in these studies

Provectus Biopharmaceuticals Receives Notice of Allowance for Refractory Pediatric Solid Tumor Cancer Monotherapy and Combination Therapy Patent for PV-10® Immunotherapy from United States Patent and Trademark Office

23 Mar 21

KNOXVILLE, TN, March 23, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB:PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent application 16/412,872, which covers the use of

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

2 Mar 21

21 Apr 21

31 Dec 21

Financial summary

Financial statements Chart PVCT financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	97.23K	97.23K	97.23K	97.23K	97.23K	97.23K
Cash burn (monthly)	296.43K	41.12K	400.87K	413.63K	319.19K	340.48K
Cash used (since last report)	1.1M	152.3K	1.48M	1.53M	1.18M	1.26M
Cash remaining	-1M	-55.07K	-1.39M	-1.43M	-1.08M	-1.16M
Runway (months of cash)	-3.4	-1.3	-3.5	-3.5	-3.4	-3.4

Beta Read what these cash burn values mean

Recent insider trades

PVCT insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
10 Nov 20	Bruce Horowitz	Common Stock	Grant	Aquire A	No	No	0	800,000	0	2,227,243
10 Nov 20	Bruce Horowitz	Stock Options Comon Stock	Grant	Aquire A	No	No	0.12	2,425,000	291K	2,425,000
10 Nov 20	John Lacy III	Common Stock	Grant	Aquire A	No	No	0	100,000	0	200,000
10 Nov 20	John Lacy III	Stock Options Common Stock	Grant	Aquire A	No	No	0.2862	100,000	28.62K	100,000
10 Nov 20	Heather Raines	Common Stock	Grant	Aquire A	No	No	0	50,000	0	1,213,153

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q3 2019

PVCT institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders	Current	Prev Q	Change
Total holders	0	0
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0	0
Total shares	0	0
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Webster Bailey

Management Discussion

Total operating expenses were $4,963,576 for the year ended December 31, 2020, a decrease of $1,336,120 or 21.2% compared to the year ended December 31, 2019. The decrease was driven by our continued transformation and process improvement efforts within the Company, along with slower recruitment and treatment in clinical trials due to the effects of SARS-CoV-2. Net loss for the year ended December 31, 2020 was $6,677,587, a decrease of $244,950 or 3.5% compared to the year ended December 31, 2019, which resulted from costs incurred in connection with our preclinical and clinical trial programs and general and administrative costs.
Research and development expenses were $2,812,760 for the year ended December 31, 2020, a decrease of $1,189,254 or 29.7% compared to the year ended December 31, 2019. The decrease was due to (i) lower clinical operations due to closure of Phase III study in early 2019 and slower recruitment and treatment in clinical trials due to the effects of SARS-CoV-2, (ii) lower amortization due to patents being fully amortized, and (iii) lower payroll and related taxes due to a lower negotiated employment agreement.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: AACR, abstract, actinic, addressed, AFCO, affordable, aim, AOCL, API, area, Aru, attract, bacteria, bacterial, Bailey, behavior, Biochemistry, Biology, Black, Calgary, Canada, canceled, CB, certiorari, cGMP, chaperone, clarification, College, compelling, composition, contact, contributor, cornea, CoV, Cumming, curative, deepened, deferral, Department, depository, disagreement, disbursement, DP, ePoster, forgivable, forgiven, frequency, Gallery, gel, gemcitabine, headcount, heat, HX, HXs, immunomodulatory, immunotherapeutic, Indian, industry, intranasal, Japan, Jonathan, Kurosu, landmark, launched, leadership, Lee, legacy, lending, mCRC, MDR, Michio, microbiology, mutant, naive, Narendran, neck, NOL, Oak, oncologist, online, ophthalmology, opposition, pandemic, pari, permission, Pfizer, Pharmacy, Physiology, platform, PO, PPP, precautionary, Premium, prerequisite, Professor, prolonged, pronouncement, prophylactic, proprietarily, PRRT, QbD, RBD, referencing, refining, regaining, repair, reportedly, respiratory, revealed, Ridge, School, Seattle, shipped, shock, SIR, SITC, spectrum, spot, STING, stored, strain, Supreme, surpassed, symbol, syndrome, temperature, temporary, terminology, TGA, top, underscored, unforgiven, uploaded, UTHSC, vacant, viable, virology, Virtual, Webster, workforce, workplace, World, writ

Removed: advisory, al, Alexandra, applicability, asin, assessed, BDO, began, biomarker, breadth, Brisbane, capability, capable, cellular, characterize, Chicago, Children, choice, classify, Clinic, colon, Consortium, consultant, contrast, demonstrated, dendritic, denying, discovered, downregulation, effector, employed, England, evaluated, Experimental, exploratory, focused, functioning, Hospital, hydrogel, identify, image, imaging, immunogenic, immunologic, induce, inhibition, injected, Kettering, killer, led, lieu, listed, Liu, locally, London, low, lung, mediated, Memorial, metastasized, mild, moderate, natural, opened, ovarian, participating, pivotal, POETIC, primer, profiling, Qin, radiologic, radiotherapy, showing, signaling, Sloan, synergy, Toomey, underway, unique, USA, viral, widely, yielding

From filing 10-K 2020 FY